Phase 4 N=30 Drug Interaction Study of Colchicine and Theophylline
Healthy
Primary: Time to Reach the Maximum Plasma Concentration (Tmax) of Theophylline — 1.25; 1.5 hours — p=0.5663
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=37 Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
Schizophrenia
Primary: Change From Baseline in Weight — 1.7; 2.1 kilograms
Phase 4 N=60 Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
Diabetes · Diabetes Mellitus, Type 2
Primary: Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio) — 0.366; 1.011 percent change — p=0.849
Phase 4 N=500 Steroids for Corneal Ulcers Trial
Corneal Ulcer · Eye Infections, Bacterial
Primary: Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 3 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate — 0.48; 0.49 logMAR — p=0.82
Phase 4 N=132 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules
Onychomycosis, Toe
Primary: Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5 — 25.6 percentage of participants
Phase 4 N=401 Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32 — -0.98; -1.12 percentage of glycosylated haemoglobin — p=0.088
Phase 4 N=89 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
Generalized Anxiety Disorder
Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale
Phase 4 N=39 An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain
Chronic Pain
Primary: Change From Baseline in Pain Intensity Rating at Day 15 — -1.56 Units on a scale
Phase 4 N=24 TAP-patients With Robotic Assisted Lap Prostatectomy
Postsurgical Pain · Analgesia · Prostatectomy
Primary: The Duration of Abdominal Analgesia From Infiltration Into the TAP — 0.39; 0.44 hours
Phase 4 N=20 Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles
Peri-oral Wrinkles
Primary: Local and Systemic Adverse Events — 100 percentage of participants
Phase 4 N=58 Study of the Insomnia in Patients With Low Back Pain
Primary Insomnia
Primary: Mean Subjective Sleep Diary Derived Total Sleep Time (TST) — 316.96; 380.45; 403.47; 375.56 Minutes
Phase 4 N=419 Inner-City Anti-IgE Therapy for Asthma
Asthma
Primary: Maximum Number of Asthma Symptom Days — 1.48; 1.96 Days — p=<0.001
Phase 4 N=62 Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)
Congestive Heart Failure · Insulin Resistance
Primary: Peak VO2 — -0.38; 3.6 ml/kg/min — p=0.08
Phase 4 N=83 Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial
Postoperative Pain
Primary: Numeric Rating Scale (NRS) Pain at Rest (0-10) on Day of Surgery Prior to Discharge — 3.3; 4.2 units on a scale
Phase 4 N=133 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale